GlassScriptPhysician profile
Zeina A Nahleh
NPI 1790742476
$2,722.49
in general payments reported to CMS, 2019-2025
28 companies · $679 in 2025
The $679 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $500 · 2021: $67.24 · 2022: $292 · 2023: $263 · 2024: $381 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,323.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Athenex Pharmaceutical Division, LLC | $1,021.72 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $251.80 | 2021-2025 | |
| Janssen Biotech, INC. | $248.48 | 2021-2025 | Carvykti, Rybrevant |
| Daiichi Sankyo INC. | $137.35 | 2023-2025 | Enhertu, Datroway |
| Tersera Therapeutics LLC | $126.28 | 2024-2025 | Zoladex |
| Astrazeneca Pharmaceuticals LP | $120.60 | 2024-2025 | Enhertu, Tagrisso, Imfinzi |
| Merck Sharp & Dohme LLC | $116.95 | 2022-2025 | Keytruda, Welireg, Keytruda Qlex |
| Pfizer INC. | $88.00 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.15 | 2023-2025 | Alunbrig, Vpriv, Ninlaro |
| Eisai INC. | $62.85 | 2023-2025 | |
| Glaxosmithkline, LLC. | $57.48 | 2024 | Jemperli, Zejula |
| Servier Pharmaceuticals LLC | $52.77 | 2025 | |
| Lilly USA, LLC | $49.53 | 2019-2025 | Jaypirca, Verzenio |
| Medtronic, INC. | $43.91 | 2022 | |
| Stemline Therapeutics INC. | $37.61 | 2023-2024 | Elzonris, Orserdu |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $31.53 | 2022 | |
| Genentech, INC. | $21.33 | 2023 | Tecentriq |
| Tempus Ai, INC | $21.21 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $20.83 | 2023 | Imbruvica, Epkinly |
| Pharmacosmos Therapeutics INC. | $20.68 | 2025 | Monoferric |
| Sobi, INC | $20.02 | 2024 | |
| Myriad Genetic Laboratories, INC. | $18.40 | 2024 | Myrisk |
| Puma Biotechnology, INC. | $17.23 | 2022 | |
| Amgen INC. | $16.16 | 2021 | |
| Astellas Pharma US INC | $13.46 | 2022 | |
| Beigene USA, INC. | $13.24 | 2023 | Brukinsa |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeina Nahleh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.